IDEAYA Biosciences (IDYA) Stock Price, News & Analysis

Company Overview

IDEAYA Biosciences, Inc. is a publicly traded clinical-stage precision oncology company focused on synthetic lethality as a novel therapeutic approach for the treatment of genetically defined cancers. The company leverages its proprietary knowledge of DNA damage response and repair pathways to design small‐molecule inhibitors that selectively target tumor cells harboring specific genetic alterations. By exploiting vulnerabilities in cancer cell survival mechanisms, IDEAYA aims to develop differentiated therapies with improved efficacy and tolerability profiles.

The company’s pipeline includes multiple small‐molecule programs addressing key oncology targets. IDEAYA’s lead synthetic lethality candidates are designed to inhibit enzymes involved in DNA replication and repair, with the goal of inducing tumor-specific cell death in cancers with loss‐of‐function mutations or epigenetic alterations. In addition to its in‐house discovery efforts, IDEAYA has established collaborations with leading global biopharmaceutical companies to expand its synthetic lethality platform and accelerate clinical development.

Since its founding in 2016 and subsequent initial public offering in 2019, IDEAYA has cultivated partnerships with major industry players including Servier and GSK to co‐develop targeted therapies and share research insights. These alliances support IDEAYA’s goal of advancing multiple programs into later-stage clinical trials while retaining the flexibility to pursue new synthetic lethality targets through its integrated discovery engine.

Headquartered in South San Francisco, California, IDEAYA Biosciences operates research and development activities in the United States and collaborates with international academic and clinical centers. The company is led by an experienced management team with deep expertise in oncology drug discovery and development, positioning IDEAYA to deliver innovative, biomarker-driven therapies to patients with high unmet medical needs.

Key Stats

• Today's Range: $21.57 to $22.56
• 50-Day Range: $17.10 to $22.97
• 52-Week Range: $13.45 to $44.42
• Volume: 281,404 shs
• Average Volume: 986,084 shs
• Market Capitalization: $1.89 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $47.55
• Consensus Rating: Moderate Buy

IDEAYA Biosciences Stock Analysis - MarketRank™

IDEAYA Biosciences scored higher than 70% of companies evaluated by MarketBeat, and ranked 320th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IDEAYA Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

IDEAYA Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for IDEAYA Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.20) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IDEAYA Biosciences is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of IDEAYA Biosciences is -6.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

IDEAYA Biosciences has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.70% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in IDEAYA Biosciences has recently increased by 2.12%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IDEAYA Biosciences does not currently pay a dividend.

Dividend Growth

IDEAYA Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.19

Percentage of Shares Shorted

14.70% of the float of IDEAYA Biosciences has been sold short.

Short Interest Ratio / Days to Cover

IDEAYA Biosciences has a short interest ratio ("days to cover") of 8.5.

Change versus previous month

Short interest in IDEAYA Biosciences has recently increased by 2.12%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 1.01

News Sentiment

IDEAYA Biosciences has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for IDEAYA Biosciences this week, compared to 6 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IDEAYA Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.50% of the stock of IDEAYA Biosciences is held by insiders.

Percentage Held by Institutions

98.29% of the stock of IDEAYA Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IDYA Stock Analysis - Frequently Asked Questions

How have IDYA shares performed this year?

IDEAYA Biosciences' stock was trading at $25.70 at the start of the year. Since then, IDYA shares have decreased by 15.9% and is now trading at $21.6170.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.07.

When did IDEAYA Biosciences IPO?

IDEAYA Biosciences (IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' top institutional investors include Palumbo Wealth Management LLC (0.02%), Signaturefd LLC (0.01%) and Parallel Advisors LLC. Insiders that own company stock include Yujiro S Hata, Briseno Andres Ruiz, Paul A Stone, Jason Throne and Michael Anthony White.
View institutional ownership trends.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEAYA Biosciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), e.l.f. Beauty (ELF) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IDYA
• CIK: 1676725
• Web: www.ideayabio.com
• Phone: (650) 443-6209
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IDEAYA Biosciences: $47.55
• High Price Target: $68.00
• Low Price Target: $25.00
• Potential Upside/Downside: +115.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$274.48 million
• Net Margins: N/A
• Pretax Margin: -4,386.90%
• Return on Equity: -29.28%
• Return on Assets: -27.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.92
• Quick Ratio: 13.92

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 276.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.25 per share
• Price / Book: 1.80

Miscellaneous

• Outstanding Shares: 87,580,000
• Free Float: 85,392,000
• Market Cap: $1.93 billion
• Optionable: Optionable
• Beta: 0.03